---
schema_version: "secwatch.filing_event.v1"
accession: "0001736730-25-000092"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:51:17.573575+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CAMP4 Q3 net loss $15.1M, cash $75.3M; advances CMP-002 with up to $100M placement

## Summary
- Cash, equivalents, and marketable securities $75.3M at Sept 30, up from $39.1M at June 30.
- Private placement initially closed $50M with potential proceeds up to $100M to fund CMP-002.
- Initiated GLP toxicology studies for CMP-002; Phase 1/2 trial expected as early as H2 2026.
- Strategic decision to pursue partnership for further development of CMP-001 (urea cycle disorders).
- Net loss $15.1M for Q3 2025 vs $13.5M for Q3 2024; R&D expenses $9.4M, G&A $4.6M.

## SEC filing metadata
- accession: 0001736730-25-000092
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000092/0001736730-25-000092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000092/camp-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001736730-25-000092
- JSON: https://secwatch.observer/filing/0001736730-25-000092.json
- Plain text: https://secwatch.observer/filing/0001736730-25-000092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.